Tag: SGLT2 inhibitor

Merck and Pfizer’s diabetes therapy under US, EU review

by Selina McKee | Mar 7, 2017 | News | 0

Regulators on both sides of the Atlantic are reviewing three new submissions for medicines containing ertugliflozin, an investigational SGLT2 inhibitor being developed by Merck and Pfizer to help improve glycaemic control in adults with type II diabetes.

Read More

Liverpool and McMaster University announce £300,000 strategic research partnership
Study finds link between malaria parasites developing antimalarial drug resistance
Researchers develop ‘digital twin’ heart models to better monitor PAH NHS patients
Closed Loop and Pharmanovia investigate precision medicine combination in hypertension
US study reveals interferon combinations cause lupus symptoms and affect treatment

PharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG

E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479